Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Lysergic Acid Diethylamide Tartrate

Phase 1Small molecule

RRigshospitalet, Denmark

1

Indications

2

Total Trials

2

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Basic ScienceActive, not recruiting

Basic SciencePhase 1

Active, not recruiting

Timeline

Expected Milestones

Q4 2027

Phase 1Active, not recruiting

Basic Science

NCT05953038

Q2 2028

Phase 2Recruiting

Palliative Care

NCT05883540

Clinical

Trials by Indication[1]

Palliative Care1 trial

Lysergic Acid Diethylamide (LSD) in Palliative Care

Recruiting·UUniversity Hospital, Basel, Switzerland·Phase 2·NCT05883540·60 enrolled

Basic Science1 trial

Lysergic Acid Diethylamide Occupancy of the Serotonin 2A Receptor in the Human Brain

Active, not recruiting·RRigshospitalet, Denmark·Phase 1·NCT05953038·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Lysergic Acid Diethylamide Tartrate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lysergic Acid Diethylamide Tartrate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lysergic Acid Diethylamide Tartrate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Rigshospitalet, Denmark company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: RRigshospitalet, Denmark

Related News